Peroxisome Proliferator-Activated Receptor α Facilitates Osteogenic Differentiation in MC3T3-E1 Cells via the Sirtuin 1-Dependent Signaling Pathway |
Gong, Kai
(Department of Orthopaedics, Chengdu Military General Hospital)
Qu, Bo (Department of Orthopaedics, Chengdu Military General Hospital) Wang, Cairu (Department of Orthopaedics, Chengdu Military General Hospital) Zhou, Jingsong (Department of Orthopaedics, Chengdu Military General Hospital) Liao, Dongfa (Department of Orthopaedics, Chengdu Military General Hospital) Zheng, Wei (Department of Orthopaedics, Chengdu Military General Hospital) Pan, Xianming (Department of Orthopaedics, Chengdu Military General Hospital) |
1 | Choi, S.E., and Kemper, J.K. (2013). Regulation of SIRT1 by microRNAs. Mol. Cells 36, 385-392. DOI |
2 | Cohen-Kfir, E., Artsi, H., Levin, A., Abramowitz, E., Bajayo, A., Gurt, I., Zhong, L., D'Urso, A., Toiber, D., Mostoslavsky, R., et al. (2011). Sirt1 is a regulator of bone mass and a repressor of Sost encoding for sclerostin, a bone formation inhibitor. Endocrinology 152, 4514-4524. DOI |
3 | Desvergne, B., and Wahli, W. (1999). Peroxisome proliferatoractivated receptors: nuclear control of metabolism. Endocr. Rev. 20, 649-688. |
4 | Feng, Z., Deng, H., Du, J., Chen, D., Jiang, R., and Liang, X. (2011). Lentiviral-mediated RNAi targeting p38MAPK ameliorates high glucose-induced apoptosis in osteoblast MC3T3-E1 cell line. Indian J. Exp. Biol. 49, 94-104. |
5 | Finkel, T., Deng, C.X., and Mostoslavsky, R. (2009). Recent progress in the biology and physiology of sirtuins. Nature 460, 587-591. DOI |
6 | Gong, K., Qu, B., Liao, D., Liu, D., Wang, C., Zhou, J., and Pan, X. (2016). MiR-132 regulates osteogenic differentiation via downregulating Sirtuin1 in a peroxisome proliferator-activated receptor beta/delta-dependent manner. Biochem. Biophys. Res. Commun. 478, 260-267. DOI |
7 | Haigis, M.C., and Sinclair, D.A. (2010). Mammalian sirtuins: biological insights and disease relevance. Annu. Rev. Pathol. 5, 253-295. DOI |
8 | Issemann, I., and Green, S. (1990). Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators. Nature 347, 645-650. DOI |
9 | Lecka-Czernik, B. (2010). PPARs in bone: the role in bone cell differentiation and regulation of energy metabolism. Curr. Osteoporos. Rep. 8, 84-90. DOI |
10 | Mayoral, R., Osborn, O., McNelis, J., Johnson, A.M., Oh, D.Y., Izquierdo, C.L., Chung, H., Li, P., Traves, P.G., Bandyopadhyay, G., et al. (2015). Adipocyte SIRT1 knockout promotes PPARgamma activity, adipogenesis and insulin sensitivity in chronic-HFD and obesity. Mol. Metab. 4, 378-391. DOI |
11 | Picard, F., Kurtev, M., Chung, N., Topark-Ngarm, A., Senawong, T., Machado De Oliveira, R., Leid, M., McBurney, M.W., and Guarente, L. (2004). Sirt1 promotes fat mobilization in white adipocytes by repressing PPAR-gamma. Nature 429, 771-776. DOI |
12 | Schwartz, A.V. (2016). Efficacy of osteoporosis therapies in diabetic patients. Calcif. Tissue Int. 100, 165-173. |
13 | Qiang, L., Wang, L., Kon, N., Zhao, W., Lee, S., Zhang, Y., Rosenbaum, M., Zhao, Y., Gu, W., Farmer, S.R., et al. (2012). Brown remodeling of white adipose tissue by SirT1-dependent deacetylation of Ppargamma. Cell 150, 620-632. DOI |
14 | Qu, B., Ma, Y., Yan, M., Gong, K., Liang, F., Deng, S., Jiang, K., Ma, Z., and Pan, X. (2016). Sirtuin1 promotes osteogenic differentiation through downregulation of peroxisome proliferator-activated receptor gamma in MC3T3-E1 cells. Biochem. Biophys.Res. Commun. 478, 439-445. DOI |
15 | Raisz, L.G. (2005). Pathogenesis of osteoporosis: concepts, conflicts, and prospects. J. Clin. Invest. 115, 3318-3325. DOI |
16 | Rakel, A., Sheehy, O., Rahme, E., and LeLorier, J. (2008). Osteoporosis among patients with type 1 and type 2 diabetes. Diabetes Metab. 34, 193-205. DOI |
17 | Rodgers, J.T., Lerin, C., Haas, W., Gygi, S.P., Spiegelman, B.M., and Puigserver, P. (2005). Nutrient control of glucose homeostasis through a complex of PGC-1alpha and SIRT1. Nature 434, 113-118. DOI |
18 | Stunes, A.K., Westbroek, I., Gustafsson, B.I., Fossmark, R., Waarsing, J.H., Eriksen, E.F., Petzold, C., Reseland, J.E., and Syversen, U. (2011). The peroxisome proliferator-activated receptor (PPAR) alpha agonist fenofibrate maintains bone mass, while the PPAR gamma agonist pioglitazone exaggerates bone loss, in ovariectomized rats. BMC Endocr. Disord. 11, 11. DOI |
19 | Syversen, U., Stunes, A.K., Gustafsson, B.I., Obrant, K.J., Nordsletten, L., Berge, R., Thommesen, L., and Reseland, J.E. (2009). Different skeletal effects of the peroxisome proliferator activated receptor (PPAR)alpha agonist fenofibrate and the PPARgamma agonist pioglitazone. BMC Endocr. Disord. 9, 10. DOI |
20 | Takano, M., Otsuka, F., Matsumoto, Y., Inagaki, K., Takeda, M., Nakamura, E., Tsukamoto, N., Miyoshi, T., Sada, K.E., and Makino, H. (2012). Peroxisome proliferator-activated receptor activity is involved in the osteoblastic differentiation regulated by bone morphogenetic proteins and tumor necrosis factor-alpha. Mol. Cell Endocrinol. 348, 224-232. DOI |
21 | Wang, Y., Liang, Y., and Vanhoutte, P.M. (2011). SIRT1 and AMPK in regulating mammalian senescence: a critical review and a working model. FEBS Lett. 585, 986-994. DOI |
22 | Zhang, W.L., Meng, H.Z., Yang, R.F., Yang, M.W., Sun, G.H., Liu, J.H., Shi, P.X., Liu, F., and Yang, B. (2016). Melatonin suppresses autophagy in type 2 diabetic osteoporosis. Oncotarget 7, 52179-52194. DOI |
23 | Yao, H., and Rahman, I. (2012). Perspectives on translational and therapeutic aspects of SIRT1 in inflammaging and senescence. Biochem. Pharmacol. 84, 1332-1339. DOI |
24 | Yoon, J.C., Puigserver, P., Chen, G., Donovan, J., Wu, Z., Rhee, J., Adelmant, G., Stafford, J., Kahn, C.R., Granner, D.K., et al. (2001). Control of hepatic gluconeogenesis through the transcriptional coactivator PGC-1. Nature 413, 131-138. DOI |
25 | You, L., Gu, W., Chen, L., Pan, L., Chen, J., and Peng, Y. (2014). MiR-378 overexpression attenuates high glucose-suppressed osteogenic differentiation through targeting CASP3 and activating PI3K/Akt signaling pathway. Int. J. Clin. Exp. Pathol. 7, 7249-7261. |
26 | Borra, M.T., Smith, B.C., and Denu, J.M. (2005). Mechanism of human SIRT1 activation by resveratrol. J. Biol. Chem. 280, 17187-17195. DOI |
27 | Ali, A.A., Weinstein, R.S., Stewart, S.A., Parfitt, A.M., Manolagas, S.C., and Jilka, R.L. (2005). Rosiglitazone causes bone loss in mice by suppressing osteoblast differentiation and bone formation. Endocrinology. 146, 1226-1235. DOI |
28 | Backesjo, C.M., Li, Y., Lindgren, U., and Haldosen, L.A. (2006). Activation of Sirt1 decreases adipocyte formation during osteoblast differentiation of mesenchymal stem cells. J. Bone Miner Res. 21, 993-1002. DOI |
29 | Blakytny, R., Spraul, M., and Jude, E.B. (2011). Review: The diabetic bone: a cellular and molecular perspective. Int. J. Low Extrem Wounds. 10, 16-32. DOI |
30 | Chang, F., Jaber, L.A., Berlie, H.D., and O'Connell, M.B. (2007). Evolution of peroxisome proliferator-activated receptor agonists. Ann. Pharmacother. 41, 973-983. DOI |
![]() |